NCT04483297View on ClinicalTrials.gov

First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS)

PHASE1TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

November 27, 2023

Study Completion Date

January 30, 2024

Conditions
Degenerative SpondylolisthesisSpinal Stenosis
Interventions
DRUG

AK1320 MS

AK1320 MS + Local Autologous Bone + Posterior Fixation. Ascending Dose.

OTHER

Control

Local Autologous Bone + Posterior Fixation

Trial Locations (7)

T5H 3V9

Royal Alexandra Hospital, Edmonton

B3H 3A7

Queen Elizabeth II Health Sciences Centre, Halifax

N6A5W9

London Health Sciences Centre, London

M4N3M5

Sunnybrook Health Sciences Centre, Toronto

H3G 1A4

Montreal General Hospital, Montreal

H4J 1C5

Hôpital Sacré-Coeur de Montréal, Montreal

G1J1Z4

Centre Hospitalier Universitaire de Québec Laval, Québec

Sponsors
All Listed Sponsors
collaborator

Emergent Clinical Consulting, LLC

INDUSTRY

lead

Asahi Kasei Pharma Corporation

INDUSTRY

NCT04483297 - First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS) | Biotech Hunter | Biotech Hunter